Working with TipRanks
Follow Us
Stocks
ETFs
Options
Commodities
Crypto
Currency
Pro Newsletters
Research Tools
Calendars
Economic Indicators
Calculators
Education
About Us
Working with TipRanks
Follow Us
Teva Pharmaceutical (DE:TEV)
FRANKFURT:TEV
Teva Pharmaceutical (TEV) Stock Price & Analysis
21 Followers
TEV Stock Chart & Stats
Day’s Range€0 - €0
52-Week Range€7.00 - €16.25
Previous Close€15.55
Volume520.00
Average Volume (3M)5.87K
Market Cap
€17.89B
Enterprise Value€34.00B
Total Cash (Recent Filing)$3.23B
Total Debt (Recent Filing)$20.15B
Price to Earnings (P/E)―
Beta1.07
Next Earnings
Jul 31, 2024EPS Estimate
€0.52Last Dividend Ex-Date
Nov 27, 2017Dividend YieldN/A
Share Statistics
EPS (TTM)-0.38
Shares Outstanding1,132,640,597
10 Day Avg. Volume2,620
30 Day Avg. Volume5,865
Standard DeviationN/A
R-SquaredN/A
AlphaN/A
Financial Highlights & Ratios
Price to Book (P/B)-1.28
Price to Sales (P/S)1.14
Price to Cash Flow (P/CF)4.10
P/FCF Ratio3.80
Enterprise Value/Market CapN/A
Enterprise Value/Revenue2.15
Enterprise Value/Gross Profit4.45
Enterprise Value/Ebitda33.66
Forecast
1Y Price Target
€18.37Price Target Upside17.72% Upside
Rating ConsensusStrong Buy
Number of Analyst Covering8
Teva Pharmaceutical News
Bulls Say, Bears Say
Bulls Say
Growth And ValuationTeva appears to have steadied its ship, launching a range of new drugs and achieving margin growth across all of its three primary business segments.
Pipeline And ApprovalsBiosimilar launches in 2024/2025 and key pipeline programs readouts in 2H24 are expected to drive multiple expansion.
Product LaunchesThe company has recently launched a range of new drugs, including an extended release version of Teva's treatment for tardive dyskinesia (TD) and Huntington's disease (HD) chorea, as well as generic versions of the blockbuster drug Humira, plaque psoriasis and psoriatic arthritis drug Stelara, and GLP-1 treatment for type 2 diabetes, Victoza.
Bears Say
Financial PerformanceGross margins across TEVA's business have come in below expectations over the past year.
Market PerformanceTEVA's North America generics business has underperformed expectations, and biosimilars are unlikely to replace lost gRevlimid sales in 2026+.
Revenue ExpectationsManagement declined to set high expectations for 2H24 revenue capture from biosimilar Humira.
---
Options Prices
Currently, No data available
---
Ownership Overview
0.66% Insiders
16.15% Mutual Funds
2.92% Other Institutional Investors
80.27% Public Companies and
Individual Investors
TEV FAQ
What was Teva Pharmaceutical’s price range in the past 12 months?
Teva Pharmaceutical lowest stock price was €7.00 and its highest was €16.25 in the past 12 months.
What is Teva Pharmaceutical’s market cap?
Currently, no data Available
When is Teva Pharmaceutical’s upcoming earnings report date?
Teva Pharmaceutical’s upcoming earnings report date is Jul 31, 2024 which is in 9 days.
How were Teva Pharmaceutical’s earnings last quarter?
Teva Pharmaceutical released its earnings results on May 08, 2024. The company reported €0.441 earnings per share for the quarter, missing the consensus estimate of €0.472 by -€0.031.
Is Teva Pharmaceutical overvalued?
According to Wall Street analysts Teva Pharmaceutical’s price is currently Undervalued.
Does Teva Pharmaceutical pay dividends?
Teva Pharmaceutical pays a Quarterly dividend of €0.07 which represents an annual dividend yield of N/A. See more information on Teva Pharmaceutical dividends here
What is Teva Pharmaceutical’s EPS estimate?
Teva Pharmaceutical’s EPS estimate is €0.52.
How many shares outstanding does Teva Pharmaceutical have?
Teva Pharmaceutical has 1,132,592,400 shares outstanding.
What happened to Teva Pharmaceutical’s price movement after its last earnings report?
Teva Pharmaceutical reported an EPS of €0.441 in its last earnings report, missing expectations of €0.472. Following the earnings report the stock price went up 17.647%.
Which hedge fund is a major shareholder of Teva Pharmaceutical?
Among the largest hedge funds holding Teva Pharmaceutical’s share is Slate Path Capital LP. It holds Teva Pharmaceutical’s shares valued at 380M.
---
Teva Pharmaceutical Stock Smart Score
Unlock Smart Score
1
2
3
4
5
6
7
8
9
10
Analyst Consensus
Strong Buy
Average Price Target:
€18.37 (17.72% Upside)
€18.37 (17.72% Upside)
Blogger Sentiment
Bullish
DE:TEV Sentiment 90%
Sector Average 71%
Sector Average 71%
Insider Transactions
Sold Shares
Worth $9.6M over
the Last 3 Months
the Last 3 Months
News Sentiment
Neutral
Bullish news 50%
Bearish news 50%
Bearish news 50%
Technicals
SMA
Positive
20 days / 200 days
Momentum
114.12%
12-Months-Change
Fundamentals
Return on Equity
-6.08%
Trailing 12-Months
Asset Growth
-1.57%
Trailing 12-Months
Company Description
Teva Pharmaceutical
Teva Pharmaceutical Industries Ltd. engages in the development and production of medicines. Its products include medicines for cardiovascular diseases, pain relievers, obesity, cancer and supportive care, infectious diseases and human immunodeficiency viruses, and colds and coughs. The company was founded in 1901 and is headquartered in Petah Tikva, Israel.
---
TEV Company Deck
---
TEV Earnings Call
Q1 2024
0:00 / 0:00
---
TEV Revenue Breakdown
54.45% North America
32.42% Europe
13.12% International Markets
---
TEV Stock 12 Month Forecast
Average Price Target
€18.37
▲(17.72% Upside)
Technical Analysis
Best Analysts Covering TEV
1 Year
1 Year Success Rate
13/18 ratings generated profit
1 Year Average Return
+31.27%
reiterated a buy rating 27 days ago
Copying Balaji Prasad's trades and holding each position for 1 Year would result in 72.22% of your transactions generating a profit, with an average return of +31.27% per trade.
---